September 2014 Issue of The Medicine Maker

If you work in the development or manufacture of drugs and biologics – this is your magazine.

New vaccines, experimental treatments for patients, and cash donations make their mark on the Ebola outbreak.

Top food and pharma fugitives are named and shamed.

In October, CPhI Worldwide 2014, along with ICSE, P-MEC and InnoPack, comes to the City of Light - Paris.

European Commission (EC) plans to transfer governance of the medicines dossier from health to enterprise has upset public health NGOs.

Could tackling bottlenecks in early-stage R&D provide a faster route to the clinic?

Lilly and Sanofi go head-to-head on a diabetes drug. Meanwhile, Hospira sues the FDA over a new generic approval.

We speak to Derek Gatherer from the Division of Biomedical and Life Sciences at Lancaster University, UK, to get an overview of the Ebola outbreak.

After years of intense criticism, the European Parliament has adopted a new regulation for clinical trials that will replace the current EU Clinical Trials Directive by mid-2016.

Is there a ‘safe’ hold time for sterilized items? And, if so, how can those hold times be reliably validated?

We now know more than ever before about the complex ecosystem of bacteria, fungi, and viruses within our bodies

The World Health Organization has compiled a list of 17 tropical diseases that deserve higher priority.

How are changing trends and fresh challenges affecting the world of medicine manufacture?

Guillaume Plane takes us on a tour of the facility of the near future.

Today’s pharmaceutical manufacturing operations capture huge amounts of data. Unfortunately, in many cases the data pass by without actual context.

Maximizing operational excellence – what have we learned and where do we go next?

Antibiotics were once hailed as wonder drugs in the war against infection, but now it looks like bacteria might have the upper hand. How can we turn the tide?

Manufacturing stem cells for use in research is one thing; doing it on a commercial scale is an entirely different ballgame.

An FDA Warning Letter can be a real wake up call. How can you address the root of the problem?

Sitting Down With… Wim Leereveld, founder and CEO of the Access to Medicine Foundation